A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PROSERA)
The primary objective of the study is to determine the effect of seralutinib vs. placebo on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III.
Study details
Study-ID: NCT05934526, 2023-503614-80-00
Study-ID: NCT05934526, 2023-503614-80-00
DZL Disease Area: PH
DZL Disease Area: PH
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL discovery-based, DZL recruiting center, DZL on steering board
DZL Role: DZL discovery-based, DZL recruiting center, DZL on steering board
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: BREATH, TLRC, UGMLC
DZL Participating Sites: BREATH, TLRC, UGMLC
Start Date: 01.12.2023
Completion Date: 31.12.2025
Status: Closed
Status: Closed
DZL discovery-based, DZL recruiting center, DZL on steering board
Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu.
Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.
